| [1] |
Silver RM, Branch DW. Placenta accreta spectrum[J]. N Engl J Med 2018，378(16)：1529-1536.
|
| [2] |
Matsuzaki S, Mandelbaum RS, Sangara RN, et al. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States[J]. Am J Obstet Gynecol，2021，225(5)：534.e1-534.e38.
|
| [3] |
Ming Y, Zeng X, Zheng T, et al. Epidemiology of placenta accreta spectrum disorders in Chinese pregnant women: a multicenter hospital-based study[J]. Placenta，2022，126：133-139.
|
| [4] |
Jauniaux E, Chantraine F, Silver RM, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology[J]. Int J Gynaecol Obstet，2018，140(3)：265-273.
|
| [5] |
中华医学会围产医学分会，中华医学会妇产科学分会产科学组. 胎盘植入诊治指南(2015)[J/OL]. 中华产科急救电子杂志，2016，5(1)：26-31.
|
| [6] |
Jauniaux E, Burton GJ. Pathophysiology of placenta accreta spectrum disorders: a review of current findings[J]. Clin Obstet Gynecol，2018，61(4)：743-754.
|
| [7] |
Ma J, Liu Y, Guo Z, et al. The diversity of trophoblast cells and niches of placenta accreta spectrum disorders revealed by single-cell RNA sequencing[J]. Front Cell Dev Biol，2022，10：1-16.
|
| [8] |
Silver RM. Abnormal placentation: placenta previa, vasa previa, and placenta accreta[J]. Obstet Gynecol，2015，126(3)：654-668.
|
| [9] |
Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries[J]. BJOG，2016，123(8)：1348-1355.
|
| [10] |
Al-Lami RA, Salih SM, Sibai BM. In vitro fertilization as an independent risk factor for placenta accreta spectrum[J]. Am J Obstet Gynecol，2021，225(6)：699.
|
| [11] |
Guo Z, Han X, Zheng W, et al. Placenta accreta spectrum among multiple gestation: a retrospective analysis based on a Chinese population[J]. Front Endocrinol (Lausanne)，2022，13：1-7.
|
| [12] |
Miller HE, Leonard SA, Fox KA, et al. Placenta accreta spectrum among women with twin gestations[J]. Obstet Gynecol，2021，137(1)：132-138.
|
| [13] |
Cali G, Forlani F, Lees C, et al. Prenatal ultrasound staging system for placenta accreta spectrum disorders[J]. Ultrasound Obstet Gynecol，2019，53(6)：752-760.
|
| [14] |
Zheng W, Zhang H, Ma J, et al. Validation of a scoring system for prediction of obstetric complications in placenta accreta spectrum disorders[J]. J Matern Fetal Neona，2022，35(21)：4149-4155.
|
| [15] |
Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, et al. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders[J]. Int J Gynaecol Obstet，2019，146(1)：20-24.
|
| [16] |
Meng X, Xie L, Song W. Comparing the diagnostic value of ultrasound and magnetic resonance imaging for placenta accreta: a systematic review and meta-analysis[J]. Ultrasound Med Biol，2013，39(11)：1958-1965.
|
| [17] |
Familiari A, Liberati M, Lim P, et al. Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis[J]. Acta Obstet Gynecol Scand，2018，97(5)：507-520.
|
| [18] |
Jauniaux E, Bhide A, Kennedy A, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: prenatal diagnosis and screening[J]. Int J Gynaecol Obstet，2018，140(3)：274-280.
|
| [19] |
Phipps EA, Thadhani R, Benzing T, et al. Pre-eclampsia: pathogenesis, novel diagnostics and therapies[J]. Nat Rev Nephrol，2019，15(5)：275-289.
|
| [20] |
Guo Z, Yang H, Ma J. Maternal circulating biomarkers associated with placenta accreta spectrum disorders[J]. Chin Med J (Engl)，2023，136(8)：995-997.
|
| [21] |
Afshar Y, Dong J, Zhao P, et al. Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders[J]. Nat Commun，2021，12(1)：1-14.
|
| [22] |
Guo Z, Han X, Zhang H, et al. Association between pre-delivery coagulation indicators and invasive placenta accreta spectrum[J]. Clin Appl Thromb Hemost，2022，28：1-8.
|
| [23] |
Allen L, Jauniaux E, Hobson S, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: nonconservative surgical management[J]. Int J Gynaecol Obstet，2018，140(3)：281-290.
|
| [24] |
Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study[J]. Am J Obstet Gynecol，2022，226(6)：839.e1-839.e24.
|
| [25] |
Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline No. 27a[J]. BJOG，2019，126(1)：e1-e48.
|
| [26] |
Hobson SR, Kingdom JC, Murji A, et al. No. 383-Screening, diagnosis, and management of placenta accreta spectrum disorders[J]. J Obstet Gynaecol Can，2019，41(7)：1035-1049.
|
| [27] |
Matsuo K, Youssefzadeh AC, Mandelbaum RS, et al. Hospital surgical volume-outcome relationship in caesarean hysterectomy for placenta accreta spectrum[J]. BJOG，2022，129(6)：986-993.
|
| [28] |
Bhide A. BJOG mini commentary on placenta accreta spectrum-variations in clinical practice and maternal morbidity between UK and France: a population-based comparative study[J]. BJOG，2022，129(10)：1686.
|
| [29] |
Wang Q, Ma J, Zhang H, et al. Conservative management versus cesarean hysterectomy in patients with placenta increta or percreta[J]. J Matern Fetal Neonatal Med，2022，35(10)：1944-1950.
|
| [30] |
Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta[J]. Obstet Gynecol，2010，115(3)：526-534.
|
| [31] |
Sentilhes L, Kayem G, Silver RM. Conservative management of placenta accreta spectrum[J]. Clin Obstet Gynecol，2018，61(4)：783-794.
|
| [32] |
Sentilhes L, Kayem G, Ambroselli C, et al. Fertility and pregnancy outcomes following conservative treatment for placenta accreta[J]. Hum Reprod，2010，25(11)：2803-2810.
|
| [33] |
Grover B, Einerson BD, Keenan KD, et al. Patient-reported health outcomes and quality of life after peripartum hysterectomy for placenta accreta spectrum[J]. Am J Perinatol，2022，39(3)：281-287.
|